- Home
- GUTS
GUTS
FRACTYL HEALTH INC
as 12-17-2024 4:00pm EST
Stocks
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 110.1M | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 275.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.74 - $14.50 | Next Earning Date: | 02-02-2025 |
| Revenue: | $97,000 | Revenue Growth: | -14.16% |
| Revenue Growth (this year): | -57.5% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of FRACTYL HEALTH INC (GUTS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Caplan Jay David | GUTS | President, Chief Product Off. | Nov 10 '24 | Sell | $2.47 | 64,197 | $158,540.91 | 153,544 | |
| Rajagopalan Harith | GUTS | Chief Executive Officer | Nov 10 '24 | Sell | $2.47 | 96,517 | $238,358.38 | 491,329 |
Latest FRACTYL HEALTH INC News
GUTS Breaking Stock News: Dive into GUTS Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewswire
9 days ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewswire
22 days ago
Fractyl Health to Participate in the Upcoming December Conferences
Simply Wall St.
a month ago
Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023)
GlobeNewswire
a month ago
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
a month ago
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
GlobeNewswire
a month ago
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
GlobeNewswire
2 months ago
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
Compare GUTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GUTS FRACTYL HEALTH INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.